Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Will Submit Data To FDA On Lexiva’s Comparability To Kaletra

This article was originally published in The Pink Sheet Daily

Executive Summary

Results of a GSK/Vertex head-to-head clinical study indicate that Lexiva plus ritonavir is comparable to Abbott’s Kaletra in treatment-naive HIV patients.

You may also be interested in...



Lexiva’s Updated Label Allows Concomitant PPI Treatment

GSK/Vertex’s post-marketing study found that proton pump inhibitor use does not lessen the protease inhibitor’s efficacy.

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.

Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down

The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel